Stock Track | Clover Bio-B Soars 6.99% Intraday on Positive Phase I RSV Vaccine Data Showing 60-80% Superiority Over GSK's Arexvy

Stock Track03-25

Clover Bio-B's stock surged 6.99% during intraday trading on Wednesday, following the release of encouraging clinical trial results for its respiratory syncytial virus (RSV) vaccine candidate.

The company reported additional Phase I data from a U.S. study showing that its SCB-1019 vaccine, when used as a heterologous booster in adults aged 60-85, generated approximately 60-80% higher geometric mean titers of RSV-A and RSV-B neutralizing antibodies compared to a booster dose of GSK's established vaccine, Arexvy. An exploratory analysis also suggested SCB-1019 restored antibody levels to 120-135% of the peak seen after an initial Arexvy dose, outperforming the homologous Arexvy booster.

With over 40% of eligible U.S. adults having received an initial RSV vaccine dose, the data positions Clover's candidate in a potential revaccination market. The company also noted its RSV combination vaccine candidates have progressed to Phase II trials, broadening their potential protective scope.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193251556?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193251556","market":"hk","top_or_hot":-1,"title":"Stock Track | Clover Bio-B Soars 6.99% Intraday on Positive Phase I RSV Vaccine Data Showing 60-80% Superiority Over GSK's Arexvy","media":"Stock Track","content":"<p>Clover Bio-B's stock surged 6.99% during intraday trading on Wednesday, following the release of encouraging clinical trial results for its respiratory syncytial virus (RSV) vaccine candidate.</p><p>The company reported additional Phase I data from a U.S. study showing that its SCB-1019 vaccine, when used as a heterologous booster in adults aged 60-85, generated approximately 60-80% higher geometric mean titers of RSV-A and RSV-B neutralizing antibodies compared to a booster dose of GSK's established vaccine, Arexvy. An exploratory analysis also suggested SCB-1019 restored antibody levels to 120-135% of the peak seen after an initial Arexvy dose, outperforming the homologous Arexvy booster.</p><p>With over 40% of eligible U.S. adults having received an initial RSV vaccine dose, the data positions Clover's candidate in a potential revaccination market. The company also noted its RSV combination vaccine candidates have progressed to Phase II trials, broadening their potential protective scope.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Clover Bio-B Soars 6.99% Intraday on Positive Phase I RSV Vaccine Data Showing 60-80% Superiority Over GSK's Arexvy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Clover Bio-B Soars 6.99% Intraday on Positive Phase I RSV Vaccine Data Showing 60-80% Superiority Over GSK's Arexvy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-25 09:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clover Bio-B's stock surged 6.99% during intraday trading on Wednesday, following the release of encouraging clinical trial results for its respiratory syncytial virus (RSV) vaccine candidate.</p><p>The company reported additional Phase I data from a U.S. study showing that its SCB-1019 vaccine, when used as a heterologous booster in adults aged 60-85, generated approximately 60-80% higher geometric mean titers of RSV-A and RSV-B neutralizing antibodies compared to a booster dose of GSK's established vaccine, Arexvy. An exploratory analysis also suggested SCB-1019 restored antibody levels to 120-135% of the peak seen after an initial Arexvy dose, outperforming the homologous Arexvy booster.</p><p>With over 40% of eligible U.S. adults having received an initial RSV vaccine dose, the data positions Clover's candidate in a potential revaccination market. The company also noted its RSV combination vaccine candidates have progressed to Phase II trials, broadening their potential protective scope.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1193251556","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193251556","pubTimestamp":1774402558,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Clover Bio-B's stock surged 6.99% during intraday trading on Wednesday, following the release of encouraging clinical trial results for its respiratory syncytial virus (RSV) vaccine candidate.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B"},"translate_title":"个股追踪|三叶草生物-B盘中飙升6.99%，因I期RSV疫苗数据阳性显示优于GSK的Arexvy 60-80%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"Clover Bio-B's stock surged 6.99% during intraday trading on Wednesday, following the release of encouraging clinical trial results for its respiratory syncytial virus (RSV) vaccine candidate.The company reported additional Phase I data from a U.S. study showing that its SCB-1019 vaccine, when used as a heterologous booster in adults aged 60-85, generated approximately 60-80% higher geometric mean titers of RSV-A and RSV-B neutralizing antibodies compared to a booster dose of GSK's established vaccine, Arexvy. An exploratory analysis also suggested SCB-1019 restored antibody levels to 120-135% of the peak seen after an initial Arexvy dose, outperforming the homologous Arexvy booster.With over 40% of eligible U.S. adults having received an initial RSV vaccine dose, the data positions Clover's candidate in a potential revaccination market. The company also noted its RSV combination vaccine candidates have progressed to Phase II trials, broadening their potential protective scope.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193251556","isCrawlerRequest":true}